Eagle's Eye View: Your Weekly CV Update From ACC.org

American College of Cardiology
undefined
Sep 12, 2024 • 11min

Eight Practice-Changing Trials Featured at ESC Congress 2024

In this special edition of Eagle's Eye View, Dr. Eagle summarizes the most important trials that were featured at the ESC Congress 2024, August 30 to September 2—eight trials that could have significant influence on your day-to-day practice. They include: FINEARTS-HF, exploring the benefits of finerenone in patients with HFmrEF or HFpEF; SCOFF, asking if fasting prior to cath lab procedures is necessary; SENIOR-RITA on CV management in frail adults; SHAM-PVI, exploring pulmonary vein isolation vs. sham intervention in patients with asymptomatic AFib; ASSURE DES, examining continuing vs. interruptive aspirin therapy before noncardiac surgery in patients with DES; Stop-or-Not, on the continuation vs. discontinuation of RASIs prior to major noncardiac surgery; ABYSS, exploring the impact of interrupting or continuing beta-blocker treatment in patients with a history of MI; and RESHAPE-HF2, on the impact of M-TEER on patients with FMR and symptomatic HF. Subscribe to Eagle's Eye View
undefined
Sep 11, 2024 • 8min

Mechanical Circulatory Support in Infarct-Related Cardiogenic Shock, Anticoagulation Benefit in Device-Detected AFib, Semaglutide in HFpEF Patients

Discover the latest advancements in cardiovascular care! The discussion includes the use of temporary mechanical support for cardiogenic shock following a heart attack. Learn about the benefits of anticoagulation in patients with device-detected atrial fibrillation. The effectiveness of semaglutide in treating heart failure with mildly reduced or preserved ejection fraction is also highlighted. These insights aim to improve treatment strategies and patient outcomes.
undefined
Sep 4, 2024 • 10min

SGLT2 Inhibitors vs. GLP-1 RAs in Diabetes, MRI Lesions After TAVR, Perioperative Management and Anticoagulants

In this week's View, Dr. Eagle looks at the kidney and cardiovascular effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes. He then explores the prognostic ability of diffusion-weighted brain MRI lesions after TAVR. Finally, Dr. Eagle discusses perioperative management of patients taking direct oral anticoagulants, particularly those being considered for noncardiac surgery. Subscribe to Eagle's Eye View
undefined
Aug 28, 2024 • 11min

Social Determinants of Health in Cardiology, Aortopathy in Children, Cardiac CT Following Left Atrial Appendage Occlusion

In this week's View, Dr. Eagle looks at the 2024 ACC/AHA key data elements and definitions for social determinants of health in cardiology. He then explores key points of management of aortopathy in children. Finally, Dr. Eagle discusses the recent position statement on the use of cardiac CT following left atrial appendage occlusion. Subscribe to Eagle's Eye View
undefined
Aug 21, 2024 • 11min

Genetics and Risk in Aortic Disease, Plant vs. Animal Fat in Cardiovascular Outcomes, Management of Cardiac Sarcoidosis

In this week's View, Dr. Eagle looks at the potential role of genetics in predicting risk in people with aortic disease. He then compares plant and animal fat intake in overall cardiovascular disease outcomes. Finally, Dr. Eagle discusses a clinical consensus statement on the management of cardiac sarcoidosis from the European community. Subscribe to Eagle's Eye View
undefined
Aug 14, 2024 • 8min

Update to ACC/AHA Heart Failure Performance Measures; Quadruple Therapy and HF; ACEi, ARBs, and Chronic Kidney Disease

Dr. Eagle, a renowned expert in cardiology, shares fresh insights on heart failure management. He delves into the 2024 updates to clinical performance measures, emphasizing new metrics aimed at improving patient care. The conversation shifts to the promising benefits of rapidly starting quadruple therapy for newly diagnosed heart failure. Dr. Eagle also reviews clinical trials on the effectiveness of ACE inhibitors and ARBs for patients with advanced chronic kidney disease, highlighting important implications for treatment strategies.
undefined
Aug 7, 2024 • 7min

Pulmonary Hypertension and HF, Obesity in Adolescents, Noncardiac Surgery After TAVR

In this week's View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health. Finally, Dr. Eagle discusses a national analysis of the timing of noncardiac surgery following transcatheter aortic valve replacement (TAVR): is there an optimal time for surgery after TAVR? Subscribe to Eagle's Eye View
undefined
Jul 31, 2024 • 10min

Fenestrated-Branched Endovascular Aortic Repair, Mortality and PCI, Lp(a) and Calcific Aortic Stenosis Progression

In this week's View, Dr. Eagle looks at a prospective multicenter cohort study that examined early and late aortic-related mortality and rupture after fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms. He then explores periprocedural mortality in patients having PCI and a rise in biomarkers. Finally, Dr. Eagle discusses a systemic review and meta-analysis of lipoprotein(a) and calcific aortic valve stenosis progression. Subscribe to Eagle's Eye View
undefined
Jul 24, 2024 • 9min

Diuretics and HF, Implantable Cardioverter-Defibrillators and the Tricuspid Valve and Right Ventricle, Neurohormonal Blockade and HF

In this week's View, Dr. Eagle looks at a study comparing three diuretic regimens in ambulatory congested heart failure (HF) patients (DEA-HF). He then explores a randomized trial that investigates the effects of implantable cardioverter-defibrillator (ICD) leads on the tricuspid valve and right ventricle. Finally, Dr. Eagle discusses the effects of rapid up-titration of neurohormonal blockade in patients with acute decompensated HF. Subscribe to Eagle's Eye View
undefined
Jul 17, 2024 • 9min

Racial Differences in Diabetic Cardiomyopathy, Genetics of HCM, Semaglutide vs. Tirzepatide for Weight Loss

In this week's View, Dr. Eagle looks at the ARISE-HF trial that examined racial differences in diabetic cardiomyopathy. He then explores established and emerging implications of treatment of genetic hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the use of GLP-1 agonists, including semaglutide vs. tirzepatide for weight loss in adults with overweight or obesity. Subscribe to Eagle's Eye View

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app